BioSpace News Archive

Cadenza Bio, Inc., a pioneering preclinical biotechnology company dedicated to developing innovative small-molecule drugs for the treatment of multiple sclerosis and other demyelinating and inflammatory diseases, proudly announces the appointment of Michael A. Panzara, MD, MPH, to its esteemed board of directors.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that its Annual Report for 2023 has been published.

Regenative Labs, a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton’s Jelly connective tissue allograft for rotator cuff tears.

Rockwell Medical, Inc. announced that it entered into a new and expanded distribution agreement with BioNuclear and Atlantic Medical International, respectively.

Immunic, Inc. announced that it will host a Multiple Sclerosis Research and Development Day and participate in the following investor conferences in April.

AngioDynamics, Inc. announced that the United States Food and Drug Administration has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism, enhancing its utility in critical medical scenarios such as PE.

Krystal Biotech, Inc. announced that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 and interleukin-2, the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment, on Thursday, April 11, 2024 in Boston, MA.

Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.